The Law Office Of Abe Shainberg Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Clinical Data, Inc. In Connection With The Sale Of The Company To Forest Laboratories, Inc. – CLDA
The Law Office of Abe Shainberg is investigating the Board of Directors
of Clinical Data, Inc.
The Law Office of Abe Shainberg is investigating the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, with a consideration of up to $6.00 contingent upon commercial milestones related to the drug Viibryd. The companies said the deal is valued at $1.2 billion net of an undisclosed amount of cash acquired. The investigation concerns whether the Clinical Data Board of Directors breached their fiduciary duties to Clinical Data stockholders by failing to adequately shop the Company before entering into this transaction and whether Forest is underpaying for Clinical Data shares, thus unlawfully harming Clinical Data stockholders. According to Yahoo! Finance, at least one analyst set a price target of $46 per share of Clinical Data stock. If you own common stock in Clinical Data and wish to obtain additional information, please contact Abe Shainberg, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 425-7286, or visit http://www.ashainberglaw.com/clinical-data.html. Mr. Shainberg has expertise in prosecuting investor securities litigation, is a certified and registered arbitrator and mediator involving financial matters, and represents investors in various matters nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Cheng Yi Liang, a chemist with the U.S. Food and Drug Administration, was charged by the Securities and Exchange Commission with insider trading on information regarding upcoming FDA drug approval decisions on Tuesday.